The pivotal trial is expected to begin within three months. The RAP device had earlier received clearance from the US Food and Drug Administration (FDA) for the purpose of tattoo removal, according to Soliton.
READ:
WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS
“The
market for non-invasive cellulite treatments is about $1 billion in the US, so it
is clear that many women who are affected by the condition are interested in
finding ways to reduce or eliminate it,” said co-founder Walter Klemp.
In February this year, the company had a Regulation A+ IPO, meaning it raised money from public funding. SOLY shares have almost tripled since then, despite criticisms that the company is driving the stock with regular meaningless updates.